DOI: https://doi.org/10.22141/2224-0713.2.56.2013.85842

Effects of Cerebrolysin and its Significance

A.V. Savustyanenko

Abstract


For some decades Cerebrolysin is widely used drug in clinical practice to treat stroke, Alzheimer disease and traumatic brain injury. Due to intensive research work (until today was published more than 170 articles) its name became associated with such terms as «neurotrophic», «neuroplasticity», «multimodal effect», «disease-modifyng therapy» etc. The purpose of this review was to describe the current definition of these terms according to the effects of Cerebrolysin and remove any difficulties in its interpretation.

Keywords


Cerebrolysin; effects

References


Bornstein N., Poon W.S. Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries // Drugs Today (Barc). — 2012. — V. 48 (Suppl. A). — P. 43-61.

Cerebrolysin — product monograph // EVER Neuro Pharma. — 2010. — 84 p.

Prion protein: orchestrating neurotrophic activities / Martins V.R., Beraldo F.H., Hajj G.N. et al. // Curr. Issues Mol. Biol. — 2010. — V. 12, № 2. — P. 63-86.

Korsching S. The neurotrophic factor concept: a reexamination // J. Neurosci. — 1993. — V. 13, № 7. — P. 2739-2748.

The neurotrophic and neuroprotective effects of psychotropic agents / Hunsberger J., Austin D.R., Henter I.D., Chen G. // Dialogues Clin. Neurosci. — 2009. — V. 11, № 3. — P. 333-348.

Neuroplasticity and Rehabilitation / Editor S.A. Raskin // The Guilford Press. — 2011. — 351 p.

Masliah E., Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders // Drugs Today (Barc.). — 2012. — V. 48 (Suppl. A). — P. 3-24.

González M.E., Francis L., Castellano O. Antioxidant systemic effect of short-term Cerebrolysin administration // J. Neural. Transm. Suppl. — 1998. — V. 53. — P. 333-341.

Protective effect of FPF 1070 (cerebrolysin) on delayed neuronal death in the gerbil-detection of hydroxyl radicals with salicylic acid / Sugita Y., Kondo T., Kanazawa A. et al. // No To Shinkei. — 1993. — V. 45, № 4. — P. 325-331.

Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection / Alvarez X.A., Lombardi V.R., Fernández-Novoa L. et al. // J. Neural Transm. Suppl. — 2000. — V. 59. — P. 281-292.

Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures / Lombardi V.R., Windisch M., García M., Cacabelos R. // Methods Find. Exp. Clin. Pharmacol. — 1999. — V. 21, № 5. — P. 331-338.

Hutter-Paier, B., Eggenreich, U., Windisch, M. Effects of two protein-free peptide derivatives on passive avoidance behavior of 24-month-old rats // Arzneimittelforschung. — 1996. — V. 46, № 3. — P. 237-241.

Further evidence that Cerebrolysin protects cortical neurons from neurodegeneration in vitro / Hutter-Paier B., Grygar E., Fruhwirth M. et al. // J. Neural Transm. Suppl. — 1998. — V. 53. — P. 363-372.

Hutter-Paier, B., Steiner, E., Windisch, M. Cerebrolysin protects isolated cortical neurons from neurodegeneration after brief histotoxic hypoxia // J. Neural. Transm. Suppl. — 1998. — V. 53. — P. 351-361.

Effects of Cerebrolysin on cytoskeletal proteins after focal ischemia in rats / Schwab M., Antonow-Schlorke I., Durer U., Bauer R. // J. Neural Transm. Suppl. — 1996. — V. 47. — P. 279.

Inhibitory effect of a brain derived peptide preparation on the Ca++-dependent protease, calpain / Wronski R., Tompa P., Hutter-Paier B. et al. // J. Neural. Transm. — 2000. — V. 107, № 2. — P. 145-157.

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s disease / Rockenstein E., Torrance M., Mante M. et al. // J. Neurosci. Res. — 2006. — V. 83, № 7. — P. 1252-1261.

Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons / Hartbauer M., Hutter-Paier B., Skofitsch G., Windisch M. // J. Neural Transm. — 2001. — V. 108, № 4. — P. 459-473.

The neuroprotective effects of Cerebrolysin trade mark in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance / Rockenstein E., Adame A., Mante M. et al. // J. Neural Transm. — 2003. — V. 110, № 11. — P. 1313-1327.

Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease / Rockenstein E., Mante M., Adame A. et al. // Acta Neuropathol. — 2007. — V. 113, № 3. — P. 265-275.

Products: XPro1595 // http://fprtbio.com

The MS Disease-Modifying Medications: General information // www.nationalmssociety.org




Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта